We are finalizing the development of SARS-Cov-2 Spike RBD recombinant antigen. The antigen is produced in mammalian cells and could be used in serology assays. The product is lyophilized, which makes its shipment and storage convenient.
We now have a limited amount of R&D samples available. See the product data sheet here.